Biotech · Private company · Richmond, VA, US
Indivior Inc.
Track this companyFree. Adds Indivior Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials170 recruiting or active
Pipeline programs22From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline22
- INDV-2000Phase 2 · Opioid Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- INDV-6001Phase 2 · Moderate to Severe Opioid Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- SublocadePhase 2 · Moderate to Severe Opioid Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- SuboxonePhase 2 · Moderate to Severe Opioid Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- [14C]IDV184001ANPhase 1 · Opioid Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- INDV-2000Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- INDV-2000Phase 1 · Opioid DependenceClinicalTrials.gov · fetched Nov 12, 2026
- INDV-2000Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- SUBOXONE® sublingual filmPhase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- Blood sample collectionOpioid-use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Buprenorphine Extended-Release InjectionOpioid Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Extended-release BuprenorphineModerate to Severe Opioid-use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Not applicable - no defined interventionOpioid-use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Online survey onlyOpioid Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- PERSERISSchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- RisperidoneSchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- SublocadeOpioid Use Disorder, SevereClinicalTrials.gov · fetched Nov 12, 2026
- SUBLOCADEOpioid-use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- TM buprenorphineOpioid-use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Transmucosal BuprenorphineModerate to Severe Opioid-use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Urine sample collectionOpioid-use DisorderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials17
- INDV-6001 Multiple-Dose Pharmacokinetic StudyPHASE2 · COMPLETED · started Sep 17, 2024ClinicalTrials.gov NCT06576843 · fetched Nov 12, 2026
- Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use DisorderPHASE2 · COMPLETED · started Jun 10, 2024ClinicalTrials.gov NCT06384157 · fetched Nov 12, 2026
- Evaluating the SUBLOCADE Treatment Exit StrategyCOMPLETED · started Nov 24, 2023ClinicalTrials.gov NCT05878210 · fetched Nov 12, 2026
- SUBLOCADE Long-term OutcomesCOMPLETED · started Aug 31, 2023ClinicalTrials.gov NCT05860959 · fetched Nov 12, 2026
- Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male ParticipantsPHASE1 · COMPLETED · started Jul 10, 2023ClinicalTrials.gov NCT05974046 · fetched Nov 12, 2026
- Study of Potential CYP3A4 Induction by INDV-2000 in Healthy AdultsPHASE1 · COMPLETED · started Mar 16, 2023ClinicalTrials.gov NCT05694533 · fetched Nov 12, 2026
- Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection LocationsPHASE4 · COMPLETED · started Mar 1, 2023ClinicalTrials.gov NCT05704543 · fetched Nov 12, 2026
- Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use DisorderPHASE1 · COMPLETED · started Aug 17, 2022ClinicalTrials.gov NCT04976855 · fetched Nov 12, 2026
- Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk UsersPHASE4 · COMPLETED · started Oct 26, 2021ClinicalTrials.gov NCT04995029 · fetched Nov 12, 2026
- An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long TermTERMINATED · started Sep 20, 2020ClinicalTrials.gov NCT04577144 · fetched Nov 12, 2026
- INDV-2000 First in HumanPHASE1 · COMPLETED · started Jul 6, 2020ClinicalTrials.gov NCT04413552 · fetched Nov 12, 2026
- SUBLOCADE Rapid Initiation Extension StudyPHASE4 · COMPLETED · started Oct 21, 2019ClinicalTrials.gov NCT04060654 · fetched Nov 12, 2026
- SUBLOCADE Rapid Initiation StudyPHASE4 · COMPLETED · started Aug 29, 2019ClinicalTrials.gov NCT03993392 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral RisperidonePHASE4 · COMPLETED · started Jun 28, 2019ClinicalTrials.gov NCT03978832 · fetched Nov 12, 2026
- Evaluation of Long-term Buprenorphine Plasma ExposureCOMPLETED · started Feb 19, 2019ClinicalTrials.gov NCT03752528 · fetched Nov 12, 2026
- An Observational Study of Environmental and SocioEconomic Factors in Opioid RecoveryCOMPLETED · started Aug 1, 2015ClinicalTrials.gov NCT03604861 · fetched Nov 12, 2026
- Risks and Benefits of Naloxone PrescribingNA · COMPLETED · started Jul 1, 2014ClinicalTrials.gov NCT02535494 · fetched Nov 12, 2026
NIH awards2
- Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use DisorderFiscal year 2025 · $38.4KNIH RePORTER 5UH3DA050308-05 · fetched Nov 12, 2026
- Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use DisorderFiscal year 2024 · $287.2KNIH RePORTER 5UH3DA050308-04 · fetched Nov 12, 2026